About HLA class II histocompatibility antigen, DO beta chain
HLA class II histocompatibility antigen, DO beta chain (HLA-DOB) is a protein
from Homo sapiens identified by UniProt accession
P13765, 273 residues long.
MolForge cross-references it against 0 known binders and
71 disease associations.
Target properties
| Protein name | HLA class II histocompatibility antigen, DO beta chain |
|---|
| UniProt accession | P13765 |
|---|
| Gene | HLA-DOB |
|---|
| Organism | Homo sapiens |
|---|
| Length | 273 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (71)
Diseases linked to this target (Open Targets).
- Hashimoto's thyroiditis · score 0.26
- hypothyroidism · score 0.26
- Takayasu arteritis · score 0.26
- diabetic nephropathy · score 0.25
- proliferative diabetic retinopathy · score 0.23
- allergic rhinitis · score 0.21
- Eczematoid dermatitis · score 0.21
- rheumatoid arthritis · score 0.19
- ACPA-positive rheumatoid arthritis · score 0.19
- smoking status measurement · score 0.17
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P13765-F1 | alphafold | PREDICTED | 87.13 | — |
Amino-acid sequence (273 residues)
MGSGWVPWVV ALLVNLTRLD SSMTQGTDSP EDFVIQAKAD CYFTNGTEKV QFVVRFIFNL EEYVRFDSDV GMFVALTKLG QPDAEQWNSR LDLLERSRQA VDGVCRHNYR LGAPFTVGRK VQPEVTVYPE RTPLLHQHNL LHCSVTGFYP GDIKIKWFLN GQEERAGVMS TGPIRNGDWT FQTVVMLEMT PELGHVYTCL VDHSSLLSPV SVEWRAQSEY SWRKMLSGIA AFLLGLIFLL VGIVIQLRAQ KGYVRTQMSG NEVSRAVLLP QSC
Explore HLA class II histocompatibility antigen, DO beta chain with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets